These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 734357)

  • 1. Demonstration of high-affinity binding sites for C3a anaphylatoxin on guinea-pig platelets.
    Becker S; Hadding U; Schorlemmer HU; Bitter-Suermann D
    Scand J Immunol; 1978; 8(6):551-5. PubMed ID: 734357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of a specific C3a receptor on guinea pig platelets.
    Fukuoka Y; Hugli TE
    J Immunol; 1988 May; 140(10):3496-501. PubMed ID: 3283237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet activation: a new biological activity of guinea-pig C3a anaphylatoxin.
    Becker S; Meuer S; Hadding U; Bitter-Suermann D
    Scand J Immunol; 1978; 7(2):173-80. PubMed ID: 653315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion.
    Meuer S; Hugli TE; Andreatta RH; Hadding U; Bitter-Suermann D
    Inflammation; 1981 Dec; 5(4):263-73. PubMed ID: 6976935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic C3a analogs as specific inhibitors of C3a activity.
    Meuer S; Hadding U; Andreatta R; Bitter-Suermann D
    Immunopharmacology; 1981 Sep; 3(3):275-80. PubMed ID: 6975766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3a induced activation and stimulus specific reversible desensitization of guinea pig platelets.
    Zanker B; Rasokat H; Hadding U; Bitter-Suermann D
    Agents Actions Suppl; 1982; 11():147-57. PubMed ID: 6983827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anaphylatoxic peptide C3a of guinea pig complement. I. Purification, physicochemical and antigenetic properties.
    Meuer S; Becker S; Hadding U; Bitter-Suermann D
    Z Immunitatsforsch Immunobiol; 1978 Mar; 154(2):135-46. PubMed ID: 77089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of C3a receptor-proteins on guinea pig platelets and human polymorphonuclear leukocytes.
    Gerardy-Schahn R; Ambrosius D; Saunders D; Casaretto M; Mittler C; Karwarth G; Görgen S; Bitter-Suermann D
    Eur J Immunol; 1989 Jun; 19(6):1095-102. PubMed ID: 2666143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary injury induced by C3a and C5a anaphylatoxins.
    Stimler NP; Hugli TE; Bloor CM
    Am J Pathol; 1980 Aug; 100(2):327-48. PubMed ID: 6967702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-serotonin release by C3a and C5a: two independent pathways of activation.
    Meuer S; Ecker U; Hadding U; Bitter-Suermann D
    J Immunol; 1981 Apr; 126(4):1506-9. PubMed ID: 7204973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of C3a and C5a anaphylatoxins on guinea-pig isolated blood vessels.
    Marceau F; Hugli TE
    J Pharmacol Exp Ther; 1984 Sep; 230(3):749-54. PubMed ID: 6332191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of platelet aggregation by the complement-derived peptides C3a and C5a.
    Grossklaus C; Damerau B; Lemgo E; Vogt W
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Oct; 295(1):71-6. PubMed ID: 1004644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.
    Bautsch W; Kretzschmar T; Stühmer T; Kola A; Emde M; Köhl J; Klos A; Bitter-Suermann D
    Biochem J; 1992 Nov; 288 ( Pt 1)(Pt 1):261-6. PubMed ID: 1445269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low zone desensitization: a stimulus-specific control mechanism of cell response. Investigations on anaphylatoxin-induced platelet secretion.
    Meuer S; Zanker B; Hadding U; Bitter-Suermann D
    J Exp Med; 1982 Mar; 155(3):698-710. PubMed ID: 6977607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human platelet activation by C3a and C3a des-arg.
    Polley MJ; Nachman RL
    J Exp Med; 1983 Aug; 158(2):603-15. PubMed ID: 6604123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac anaphylaxis. Complement activation as an amplification system.
    del Balzo U; Polley MJ; Levi R
    Circ Res; 1989 Sep; 65(3):847-57. PubMed ID: 2475275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody.
    Burger R; Bader A; Kirschfink M; Rother U; Schrod L; Wörner I; Zilow G
    Clin Exp Immunol; 1987 Jun; 68(3):703-11. PubMed ID: 3498585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active site of C3a anaphylatoxin: contributions of the lipophilic and orienting residues.
    Unson CG; Erickson BW; Hugli TE
    Biochemistry; 1984 Feb; 23(4):585-9. PubMed ID: 6608957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin.
    Hugli TE; Erickson BW
    Proc Natl Acad Sci U S A; 1977 May; 74(5):1826-30. PubMed ID: 266705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue.
    Huey R; Bloor CM; Kawahara MS; Hugli TE
    Am J Pathol; 1983 Jul; 112(1):48-60. PubMed ID: 6859228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.